Search research articles
Contact Us
Filters
Showing results (1-10 of 22) with videos related to
Page
of 3
Sort By:
Essays in Biochemistry
|
October 6, 2018
Measuring microtubule dynamics
Alexander James Zwetsloot, Gokhan Tut, Anne Straube
Wellcome Open Research
|
May 31, 2024
Anti-nucleocapsid antibody levels following initial and repeat SARS-CoV-2 infections in a cohort of long-term care facility residents in England (VIVALDI)
Oliver Stirrup, Gokhan Tut, Maria Krutikov, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin
|
November 19, 2021
Changes in COVID-19 outbreak severity and duration in long-term care facilities following vaccine introduction, England, November 2020 to June 2021
Rebecca Giddings, Maria Krutikov, Tom Palmer, et al.
Age and Ageing
|
August 18, 2023
Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of long-term care facilities in the VIVALDI study
Oliver Stirrup, Madhumita Shrotri, Natalie L Adams, et al.
The Lancet. Healthy Longevity
|
June 9, 2021
Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study
Maria Krutikov, Tom Palmer, Gokhan Tut, et al.
The Lancet. Healthy Longevity
|
July 11, 2022
Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study
Madhumita Shrotri, Maria Krutikov, Hadjer Nacer-Laidi, et al.
The Lancet. Healthy Longevity
|
May 9, 2022
Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study
Maria Krutikov, Oliver Stirrup, Hadjer Nacer-Laidi, et al.
The Lancet. Healthy Longevity
|
December 22, 2021
Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England
Maria Krutikov, Tom Palmer, Gokhan Tut, et al.
The Lancet. Infectious Diseases
|
June 26, 2021
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study
Madhumita Shrotri, Maria Krutikov, Tom Palmer, et al.
Wellcome Open Research
|
October 4, 2024
VIVALDI Cohort Profile: Using linked, routinely collected data and longitudinal blood sampling to characterise COVID-19 infections, vaccinations, and related outcomes in care home staff and residents in England
Maria Krutikov, David Bone, Oliver Stirrup, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 22) with videos related to
Sort By:
Page
of 3
Essays in Biochemistry
|
October 6, 2018
Measuring microtubule dynamics
Alexander James Zwetsloot, Gokhan Tut, Anne Straube
Wellcome Open Research
|
May 31, 2024
Anti-nucleocapsid antibody levels following initial and repeat SARS-CoV-2 infections in a cohort of long-term care facility residents in England (VIVALDI)
Oliver Stirrup, Gokhan Tut, Maria Krutikov, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin
|
November 19, 2021
Changes in COVID-19 outbreak severity and duration in long-term care facilities following vaccine introduction, England, November 2020 to June 2021
Rebecca Giddings, Maria Krutikov, Tom Palmer, et al.
Age and Ageing
|
August 18, 2023
Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of long-term care facilities in the VIVALDI study
Oliver Stirrup, Madhumita Shrotri, Natalie L Adams, et al.
The Lancet. Healthy Longevity
|
June 9, 2021
Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study
Maria Krutikov, Tom Palmer, Gokhan Tut, et al.
The Lancet. Healthy Longevity
|
July 11, 2022
Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study
Madhumita Shrotri, Maria Krutikov, Hadjer Nacer-Laidi, et al.
The Lancet. Healthy Longevity
|
May 9, 2022
Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study
Maria Krutikov, Oliver Stirrup, Hadjer Nacer-Laidi, et al.
The Lancet. Healthy Longevity
|
December 22, 2021
Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England
Maria Krutikov, Tom Palmer, Gokhan Tut, et al.
The Lancet. Infectious Diseases
|
June 26, 2021
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study
Madhumita Shrotri, Maria Krutikov, Tom Palmer, et al.
Wellcome Open Research
|
October 4, 2024
VIVALDI Cohort Profile: Using linked, routinely collected data and longitudinal blood sampling to characterise COVID-19 infections, vaccinations, and related outcomes in care home staff and residents in England
Maria Krutikov, David Bone, Oliver Stirrup, et al.
Page
of 3